Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin:The Randomized, Controlled EMPA-VISION Trial

Autor: Moritz J. Hundertmark, Amanda Adler, Charalambos Antoniades, Ruth Coleman, Julian L. Griffin, Rury R. Holman, Hanan Lamlum, Jisoo Lee, Daniel Massey, Jack J.J.J. Miller, Joanne E. Milton, Shveta Monga, Ferenc E. Mózes, Areesha Nazeer, Betty Raman, Oliver Rider, Christopher T. Rodgers, Ladislav Valkovič, Eleanor Wicks, Masliza Mahmod, Stefan Neubauer

Publikováno v: Hundertmark, M J, Adler, A, Antoniades, C, Coleman, R, Griffin, J L, Holman, R R, Lamlum, H, Lee, J, Massey, D, Miller, J J J J, Milton, J E, Monga, S, Mózes, F E, Nazeer, A, Raman, B, Rider, O, Rodgers, C T, Valkovič, L, Wicks, E, Mahmod, M & Neubauer, S 2023, ' Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin : The Randomized, Controlled EMPA-VISION Trial ', Circulation, vol. 147, no. 22, pp. 1654-1669 . https://doi.org/10.1161/CIRCULATIONAHA.122.062021

BACKGROUND: Sodium–glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6991061491711a9400f62c93ebf46fa4
https://pure.au.dk/portal/da/publications/assessment-of-cardiac-energy-metabolism-function-and-physiology-in-patients-with-heart-failure-taking-empagliflozin(06821eb7-dc78-4441-a6b4-a23ac2bcfaf6).html

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.